

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA 复星医药

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a a a P ' R b C a ab)
(Stock Code: 02196)

2021 FIRST QUARTERLY REPORT

本公司董事會、監事會及高級管理層成員均於2021年4月29日（即2021年第一季末）親自出席，並親自或委託代表出席2021年第一季股東大會，討論及批准2021年第一季業績報告。本公司董事會、監事會及高級管理層成員均於2021年4月29日（即2021年第一季末）親自出席，並親自或委託代表出席2021年第一季股東大會，討論及批准2021年第一季業績報告。

本公司董事會、監事會及高級管理層成員均於2021年4月29日（即2021年第一季末）親自出席，並親自或委託代表出席2021年第一季股東大會，討論及批准2021年第一季業績報告。本公司董事會、監事會及高級管理層成員均於2021年4月29日（即2021年第一季末）親自出席，並親自或委託代表出席2021年第一季股東大會，討論及批准2021年第一季業績報告。

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang
Chairman

本公司董事會、監事會及高級管理層成員均於2021年4月29日（即2021年第一季末）親自出席，並親自或委託代表出席2021年第一季股東大會，討論及批准2021年第一季業績報告。本公司董事會、監事會及高級管理層成員均於2021年4月29日（即2021年第一季末）親自出席，並親自或委託代表出席2021年第一季股東大會，討論及批准2021年第一季業績報告。

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* for identification purposes only

1. IMPORTANT NOTICE

1. The Board of Directors (the "Board") and the Supervisory Committee (the "Supervisory Committee") of the Company have reviewed the financial statements of the Company for the year ended December 31, 2023, and have confirmed that the financial statements are true and correct, and that the Company has complied with the applicable accounting standards and regulations.
2. The Board and the Supervisory Committee have also reviewed the Company's internal control system and have confirmed that it is effective and reliable.
3. The Board and the Supervisory Committee have also reviewed the Company's business performance and have confirmed that the Company has achieved its business objectives and that its financial position is sound.
4. The Board and the Supervisory Committee have also reviewed the Company's risk management system and have confirmed that it is effective and reliable.

1. *Phragmites australis* (Cav.) Trin. ex Steud.

[illegible][illegible]

1. *Explain the following terms:*

Answer any two questions.

Items	Jan – Mar 2021
1. <i>Explain the following terms:</i>	<i>1. Expenditure</i>
2. <i>Explain the following terms:</i>	<i>2. Expenditure</i>
3. <i>Explain the following terms:</i>	<i>3. Expenditure</i>
4. <i>Explain the following terms:</i>	<i>4. Expenditure</i>
5. <i>Explain the following terms:</i>	<i>5. Expenditure</i>
6. <i>Explain the following terms:</i>	<i>6. Expenditure</i>
7. <i>Explain the following terms:</i>	<i>7. Expenditure</i>
8. <i>Explain the following terms:</i>	<i>8. Expenditure</i>
9. <i>Explain the following terms:</i>	<i>9. Expenditure</i>
10. <i>Explain the following terms:</i>	<i>10. Expenditure</i>

11. *Explain the following terms:*

Answer any two questions.

Answer any two questions.

Answer any two questions.

3. SIGNIFICANT EVENTS

▲ 2024년 12월 31일 현재 자산총액 1,000억 원, 부채총액 500억 원, 순자산총액 500억 원으로, 전년 대비 자산총액 10% 증가, 부채총액 5% 감소, 순자산총액 15% 증가한 것으로 나타났다.

(2) ▲ 2024년 12월 31일 현재

2024년 12월 31일 현재

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
자산총액	1,000억 원	900억 원	111.1%	자산총액이 전년 대비 10% 증가한 것으로 나타났다.
부채총액	500억 원	525억 원	95.2%	부채총액이 전년 대비 5% 감소한 것으로 나타났다.
순자산총액	500억 원	375억 원	133.3%	순자산총액이 전년 대비 15% 증가한 것으로 나타났다.
자산총액 구성비율	2024년 12월 31일 현재	2023년 12월 31일 현재	111.1%	자산총액이 전년 대비 10% 증가한 것으로 나타났다. (자산총액 1,000억 원, 부채총액 500억 원, 순자산총액 500억 원)
부채총액 구성비율	2024년 12월 31일 현재	2023년 12월 31일 현재	95.2%	부채총액이 전년 대비 5% 감소한 것으로 나타났다.

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan – Mar 2021	Jan – Mar 2020		
Revenue	114,111,111.11	114,111,111.11	100.00%	Revenue increased by 114,111,111.11 yuan compared with the same period last year, mainly due to the increase in sales volume.
Cost of sales	114,111,111.11	114,111,111.11	100.00%	Cost of sales increased by 114,111,111.11 yuan compared with the same period last year, mainly due to the increase in sales volume.
Gross profit	0	0	0.00%	Gross profit remained at 0 yuan compared with the same period last year.
Operating expenses	114,111,111.11	114,111,111.11	100.00%	Operating expenses increased by 114,111,111.11 yuan compared with the same period last year, mainly due to the increase in sales volume.
Operating income	0	0	0.00%	Operating income remained at 0 yuan compared with the same period last year.
Financial income	114,111,111.11	114,111,111.11	100.00%	Financial income increased by 114,111,111.11 yuan compared with the same period last year, mainly due to the increase in sales volume.
Financial expenses	114,111,111.11	114,111,111.11	100.00%	Financial expenses increased by 114,111,111.11 yuan compared with the same period last year, mainly due to the increase in sales volume.
Profit before tax	0	0	0.00%	Profit before tax remained at 0 yuan compared with the same period last year.
Income tax expense	114,111,111.11	114,111,111.11	100.00%	Income tax expense increased by 114,111,111.11 yuan compared with the same period last year, mainly due to the increase in sales volume.
Net profit	0	0	0.00%	Net profit remained at 0 yuan compared with the same period last year.

()

本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。2018年12月29日，該項授權已到期。本公司已於2019年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2020年12月29日。

1. 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。

2. 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。Non-public Offering) 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。

3. 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。CSRC) (《中國證監會行政許可申請受理單》) 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。《中國證監會行政許可項目審查一次反饋意見通知書》 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。

4. 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。

5. 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。

6. 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。21 Fosun Pharma 01) 本公司已於2017年12月29日召開股東大會，批准發行總額不超過人民幣100,000,000,000元的可轉換公司債券，並授權董事長在該授權範圍內辦理發行事宜。該項授權有效期至2018年12月29日。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

(16 Fosun Pharma 01)-

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021 Restricted Share Incentive Scheme)

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日

2021年12月31日，公司总股本为1,000,000,000股，其中：无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

2021年12月31日

* for identification purposes only

4. APPENDICES

4.1 Financial statements

Consolidated Balance Sheet 31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	31 March 2021	31 December 2020
Current assets:		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses	12,345,678	10,987,654
Other receivables	45,678,901	34,567,890
Inventory	78,901,234	67,890,123
Other current assets	123,456,789	112,345,678
Financial assets	56,789,012	45,678,901
Intangible assets	34,567,890	23,456,789
Investments	1,234,567,890	1,123,456,789
Other non-current assets	12,345,678	10,987,654
Non-current assets	1,456,789,012	1,345,678,901
Total assets	2,579,245,801	2,443,444,333
Liabilities		
Accounts payable	123,456,789	112,345,678
Other payables	234,567,890	212,345,678
Long-term debt	567,890,123	545,678,901
Other non-current liabilities	12,345,678	10,987,654
Non-current liabilities	917,800,470	881,357,211
Current liabilities	357,656,319	331,088,415
Total liabilities	1,275,456,789	1,212,445,626
Equity		
Share capital	1,000,000,000	1,000,000,000
Reserves	150,000,000	140,000,000
Other equity	12,345,678	10,987,654
Total equity	1,152,345,678	1,130,000,000
Total	2,579,245,801	2,443,444,333

Consolidated Balance Sheet (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Current liabilities:		
Short-term borrowings	1,449,441,441.44	1,449,441,441.44
Accounts payable	1,449,441,441.44	1,449,441,441.44
Prepaid expenses	1,449,441,441.44	1,449,441,441.44
Other payables	1,449,441,441.44	1,449,441,441.44
Contract liabilities	1,449,441,441.44	1,449,441,441.44
Provisions	1,449,441,441.44	1,449,441,441.44
Other current liabilities	1,449,441,441.44	1,449,441,441.44
Current liabilities	1,449,441,441.44	1,449,441,441.44
Non-current liabilities:		
Long-term borrowings	1,449,441,441.44	1,449,441,441.44
Long-term payables	1,449,441,441.44	1,449,441,441.44
Long-term provisions	1,449,441,441.44	1,449,441,441.44
Long-term other liabilities	1,449,441,441.44	1,449,441,441.44
Non-current liabilities	1,449,441,441.44	1,449,441,441.44
Equity:		
Capital	1,449,441,441.44	1,449,441,441.44
Reserves	1,449,441,441.44	1,449,441,441.44
Other equity	1,449,441,441.44	1,449,441,441.44
Equity	1,449,441,441.44	1,449,441,441.44
Total	1,449,441,441.44	1,449,441,441.44

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	31 March 2021	31 December 2020
Current assets:		
Monetary funds	¥1,234,567,890.12	¥1,123,456,789.01
Accounts receivable	¥567,890,123.45	¥456,789,012.34
Prepaid expenses	¥123,456,789.01	¥234,567,890.12
Other current assets	¥345,678,901.23	¥456,789,012.34
Financial assets	¥789,012,345.67	¥678,901,234.56
Intangible assets	¥123,456,789.01	¥234,567,890.12
Goodwill	¥456,789,012.34	¥567,890,123.45
Investments	¥234,567,890.12	¥345,678,901.23
Other non-current assets	¥123,456,789.01	¥234,567,890.12
Non-current assets:		
Property, plant and equipment	¥1,234,567,890.12	¥1,123,456,789.01
Intangible assets	¥567,890,123.45	¥456,789,012.34
Goodwill	¥123,456,789.01	¥234,567,890.12
Investments	¥345,678,901.23	¥456,789,012.34
Other non-current assets	¥234,567,890.12	¥345,678,901.23
Financial assets	¥789,012,345.67	¥678,901,234.56
Intangible assets	¥123,456,789.01	¥234,567,890.12
Goodwill	¥456,789,012.34	¥567,890,123.45
Investments	¥234,567,890.12	¥345,678,901.23
Other non-current assets	¥123,456,789.01	¥234,567,890.12
Current liabilities:		
Accounts payable	¥1,234,567,890.12	¥1,123,456,789.01
Prepaid expenses	¥567,890,123.45	¥456,789,012.34
Other current liabilities	¥123,456,789.01	¥234,567,890.12
Financial liabilities	¥345,678,901.23	¥456,789,012.34
Intangible liabilities	¥789,012,345.67	¥678,901,234.56
Goodwill	¥123,456,789.01	¥234,567,890.12
Investments	¥234,567,890.12	¥345,678,901.23
Other non-current liabilities	¥123,456,789.01	¥234,567,890.12
Financial liabilities	¥789,012,345.67	¥678,901,234.56
Intangible liabilities	¥123,456,789.01	¥234,567,890.12
Goodwill	¥456,789,012.34	¥567,890,123.45
Investments	¥234,567,890.12	¥345,678,901.23
Other non-current liabilities	¥123,456,789.01	¥234,567,890.12

Balance Sheet of the Parent Company (Continued)
31 March 2021

Items	31 March 2021	31 December 2020
Non-current liabilities:		
Long-term borrowings	1,123,456,789.12	1,123,456,789.12
Long-term payables	1,234,567,890.12	1,234,567,890.12
Long-term deferred income		
Long-term prepayments	123,456,789.12	123,456,789.12
Long-term contracts	1,234,567,890.12	1,234,567,890.12
Long-term deposits	1,234,567,890.12	1,234,567,890.12
Long-term investments	1,234,567,890.12	1,234,567,890.12
Long-term equity investments	1,234,567,890.12	1,234,567,890.12
Long-term debt investments	1,234,567,890.12	1,234,567,890.12
Long-term other investments	1,234,567,890.12	1,234,567,890.12
Equity:		
Capital	1,234,567,890.12	1,234,567,890.12
Reserves	1,234,567,890.12	1,234,567,890.12
Long-term equity investments		
Long-term debt investments		
Long-term other investments		
Long-term equity investments	1,234,567,890.12	1,234,567,890.12
Long-term debt investments	1,234,567,890.12	1,234,567,890.12
Long-term other investments	1,234,567,890.12	1,234,567,890.12
Long-term equity investments	1,234,567,890.12	1,234,567,890.12
Long-term debt investments	1,234,567,890.12	1,234,567,890.12
Long-term other investments	1,234,567,890.12	1,234,567,890.12

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Consolidated Income Statement

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

附注：本财务报表按照中国会计准则编制，与按照国际财务报告准则编制的财务报表存在差异。

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	11,125,111,754.00	11,111,111,111.00
主营业务收入	11,125,111,754.00	11,111,111,111.00
二、营业成本	7,777,777,777.00	7,777,777,777.00
主营业务成本	7,777,777,777.00	7,777,777,777.00
三、营业毛利	3,347,333,977.00	3,333,333,334.00
其他业务收入	1,111,111,111.00	1,111,111,111.00
其他业务成本	(1,111,111,111.00)	(1,111,111,111.00)
四、营业税金及附加	111,111,111.00	111,111,111.00
五、销售费用	1,111,111,111.00	1,111,111,111.00
六、管理费用	1,111,111,111.00	1,111,111,111.00
七、研发费用	1,111,111,111.00	1,111,111,111.00
八、财务费用	1,111,111,111.00	1,111,111,111.00
九、其他收益	1,111,111,111.00	1,111,111,111.00
十、公允价值变动收益	1,111,111,111.00	1,111,111,111.00
十一、资产处置收益	1,111,111,111.00	1,111,111,111.00
十二、营业利润	1,111,111,111.00	1,111,111,111.00
十三、营业外收入	1,111,111,111.00	1,111,111,111.00
十四、营业外支出	(1,111,111,111.00)	(1,111,111,111.00)
十五、利润总额	1,111,111,111.00	1,111,111,111.00
十六、所得税费用	1,111,111,111.00	1,111,111,111.00
十七、净利润	0.00	0.00
十八、其他综合收益	1,111,111,111.00	1,111,111,111.00
十九、综合收益总额	1,111,111,111.00	1,111,111,111.00
二十、每股收益	1,111,111,111.00	1,111,111,111.00

Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,111,111,111.11	1,111,111,111.11
二、营业成本	1,111,111,111.11	1,111,111,111.11
三、营业利润		
（一）营业利润		
（二）营业外收入		
（三）营业外支出		
四、利润总额		
（一）利润总额		
（二）所得税费用		
五、净利润		
（一）净利润		
（二）其他综合收益		
六、综合收益总额		
（一）综合收益总额		
（二）归属于母公司所有者的综合收益总额		
（三）归属于少数股东的综合收益总额		
七、每股收益		
（一）基本每股收益		
（二）稀释每股收益		

Legal Representative:
Wu Yifang


















































































Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Income Statement of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
1. 		
2. 		
3. 		
4. 		
5. 		
6. 		
7. 		
8. 		
9. 		
10. 		
11. 		
12. 		
13. 		
14. 		
15. 		
16. 		
17. 		
18. 		
19. 		
20. 		
21. 		
22. 		
23. 		
24. 		
25. 		
26. 		
27. 		

Income Statement of the Parent Company (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
1. Total	1,117,741,722	1,117,741,722
2. Total		
()	1,117,741,722	1,117,741,722
()	1,117,741,722	1,117,741,722

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 上海医药集团股份有限公司

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Net income	1,111,111,111	1,111,111,111
Depreciation and amortization	1,111,111,111	1,111,111,111
Provision for doubtful accounts	1,111,111,111	1,111,111,111
Provision for bad debts	1,111,111,111	1,111,111,111
Provision for employee benefits	1,111,111,111	1,111,111,111
Provision for income taxes	1,111,111,111	1,111,111,111
Provision for research and development	1,111,111,111	1,111,111,111
Provision for other non-current assets	1,111,111,111	1,111,111,111
Provision for other non-current liabilities	1,111,111,111	1,111,111,111
Provision for other non-current assets	1,111,111,111	1,111,111,111
Provision for other non-current liabilities	1,111,111,111	1,111,111,111
II. Cash flow generated from investing activities:		
Net income	1,111,111,111	1,111,111,111
Depreciation and amortization	1,111,111,111	1,111,111,111
Provision for doubtful accounts	1,111,111,111	1,111,111,111
Provision for bad debts	1,111,111,111	1,111,111,111
Provision for employee benefits	1,111,111,111	1,111,111,111
Provision for income taxes	1,111,111,111	1,111,111,111
Provision for research and development	1,111,111,111	1,111,111,111
Provision for other non-current assets	1,111,111,111	1,111,111,111
Provision for other non-current liabilities	1,111,111,111	1,111,111,111
Provision for other non-current assets	1,111,111,111	1,111,111,111
Provision for other non-current liabilities	1,111,111,111	1,111,111,111

Consolidated Statement of Cash Flow (Continued)

January – March 2021

[illegible]

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

January – March 2021

— *Journal of the American Medical Association*, 1997

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
– Net income	1,000,000	1,000,000
– Depreciation and amortization	1,000,000	1,000,000
– Increase in accounts payable	1,000,000	1,000,000
– Decrease in accounts receivable	1,000,000	1,000,000
– Increase in inventory	1,000,000	1,000,000
– Decrease in prepaid expenses	1,000,000	1,000,000
– Increase in deferred income taxes	1,000,000	1,000,000
– Decrease in other assets	1,000,000	1,000,000
– Increase in other liabilities	1,000,000	1,000,000
– Decrease in other equity	1,000,000	1,000,000
II. Cash flow generated from investing activities:		
– Purchase of property, plant, and equipment	(1,000,000)	(1,000,000)
– Purchase of intangible assets	(1,000,000)	(1,000,000)
– Sale of property, plant, and equipment	1,000,000	1,000,000
– Sale of intangible assets	1,000,000	1,000,000
– Purchase of investments	(1,000,000)	(1,000,000)
– Sale of investments	1,000,000	1,000,000
– Purchase of other assets	(1,000,000)	(1,000,000)
– Sale of other assets	1,000,000	1,000,000
– Purchase of other liabilities	(1,000,000)	(1,000,000)
– Sale of other liabilities	1,000,000	1,000,000
– Purchase of other equity	(1,000,000)	(1,000,000)
– Sale of other equity	1,000,000	1,000,000
